ANTONY, France--(BUSINESS WIRE)--STALLERGENES (Paris:GENP), a global healthcare company specialized in the diagnosis and treatment of allergies through allergen immunotherapy-based solutions, announced today the acquisition of the entire share capital of ALERGO PHARMA S.R.L., an Argentinean allergen immunotherapy (AIT) company.
The aim of the acquisition is to combine two complementary dedicated allergen immunotherapy companies, working together to provide a more comprehensive and broader range of diagnosis and treatment solutions to patients suffering from allergic respiratory diseases.
This acquisition establishes STALLERGENES among the top allergen immunotherapy pharmaceutical companies in Latin America further broadening STALLERGENES' geographic presence across the region.
"With its excellent market knowledge, an extensive distribution network and long standing relationships with allergy specialists, ALERGO PHARMA is the leader in the AIT market in Argentina," said Christian Chavy, Chief Executive Officer of STALLERGENES. "This acquisition will significantly enhance STALLERGENES' footprint in Latin America, and is consistent with our long-term strategy and commitment to fast-growing markets."
The terms of the transaction are not disclosed.
ABOUT RESPIRATORY ALLERGIES IN ARGENTINA
The prevalence of allergic rhinitis in Argentina is estimated at between 20% and 30% of the population.
The Argentinean market offers substantial potential for the development of allergen immunotherapy: 8.5 million people are sensitized and the most prevalent allergen is house dust mites. Each year, 2.3 million people are diagnosed with allergy symptoms.
Today, only 150,000 allergy sufferers are treated with allergen immunotherapy. There is therefore a strong need for innovative standardized allergen immunotherapy treatments.
